-- オキュジェン（OCGN）は、2034年満期の6.75%転換社債1億1500万ドルを私募で発行し、純手取金は約9950万ドル、オプションが全額行使された場合は1億1260万ドルになると火曜日に発表した。 同社はまた、当初の引受会社に対し、最大1500万ドルの追加社債を購入できる13日間のオプションを付与した。 オキュジェンは、調達資金のうち約3270万ドルをアベニュー・キャピタル・グループからの融資の返済に充当し、残りは一般事業資金に充当する予定だと付け加えた。 オキュジェンの株価は火曜日の取引で19%下落した。
Price: $1.50, Change: $-0.36, Percent Change: -19.19%
American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%
MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.